Study shows tofacitinib medication can fix porousness absconds in the digestive tract Kumar Jeetendra | October 6, 2020 A team of researchers led by biomedical scientist Declan F. McCole in the University of California, Riverside, has found that the medication tofacitinib, also called Xeljanz and approved by the FDA to treat rheumatoid arthritis and ulcerative colitis, can fix permeability defects in the intestine. Study results appear in the Journal of Crohn’s and Colitis. …
